Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription... حسب Thomas Hanslmeier (19949694)

الموضوعات: "…fluoroquinolone shares decreased…"

Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n... حسب Thomas Hanslmeier (19949694)

الموضوعات: "…fluoroquinolone shares decreased…"

Shares of specialist groups prescribing 1^st, 2^nd, and 3^rd antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019. حسب Thomas Hanslmeier (19949694)

الموضوعات: "…fluoroquinolone shares decreased…"

Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0). حسب Thomas Hanslmeier (19949694)

الموضوعات: "…fluoroquinolone shares decreased…"

Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.8... حسب Thomas Hanslmeier (19949694)

الموضوعات: "…fluoroquinolone shares decreased…"

Comparison of 1^st, 2^nd, and 3^rd antibiotic prescription. حسب Thomas Hanslmeier (19949694)

الموضوعات: "…fluoroquinolone shares decreased…"

UTI diagnoses by sex and physician specialty (2013–2019). حسب Thomas Hanslmeier (19949694)

الموضوعات: "…fluoroquinolone shares decreased…"

Funnel plot for testing asymmetry hypothesis using Freeman-Tukey double arcsine transformation for proportions. حسب Razieh Bidhendi-Yarandi (7139387)

الموضوعات:

Fig 3 - حسب Razieh Bidhendi-Yarandi (7139387)

الموضوعات:

Table2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX حسب Sofia Schaeffer (20379954)

"…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …"

Table1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX حسب Sofia Schaeffer (20379954)

"…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …"

2D and 3D AFM micrographs of fabricated samples (a) 5LZCM (b) 10LZCM (c) 15LZCM. حسب Md. Abu Daud (21485629)

الموضوعات:

Illumination distributions (a-c) and variations in illuminance values along the <i>x</i>-axis (d-f) of the RVL at different angles. حسب Fei Li (143236)

الموضوعات:

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"